logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

STAR CM (06698) repurchased 1,500 shares on October 28 for HK$1,228.14.

date
06:47 29/10/2026
avatar
GMT Eight
STAR CM (06698) announced that on October 28, 2026, the company repurchased 1,500 shares for HK$1,228.14, at a repurchase price of HK$0.73-0.785 per share.
STAR CM (06698) announced that on October 28, 2026, the company repurchased 1,500 shares for HK$1,228.14, at a repurchase price of HK$0.73-0.785 per share.
Related Articles
CICC: Fed rate hikes not over, but no need to rush
HK Stock
ASCLETIS-B(01672): Oral small-molecule GLP-1 ASC30 achieved a placebo-adjusted HbA1c reduction of 1.7% at week 12 in a U.S. Phase II study in subjects with diabetes
HK Stock
INNOVENT BIO (01801) reported third-quarter product revenue exceeding RMB4.7 billion, up more than 40% year on year.
CICC: Fed rate hikes not over, but no need to rush
ASCLETIS-B(01672): Oral small-molecule GLP-1 ASC30 achieved a placebo-adjusted HbA1c reduction of 1.7% at week 12 in a U.S. Phase II study in subjects with diabetes
HK Stock
INNOVENT BIO (01801) reported third-quarter product revenue exceeding RMB4.7 billion, up more than 40% year on year.
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.